BioWorld

Sep. 7, 2007

View Archived Issues

Faster Knockout Identification By Building A Better Haystack

Read More

Proteon Financing Gets $12M To Put Vasodilator Into Clinic

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Respiratory Disease Firm Pearl Raises $15.5M In First Financing

Formed last year to use particle technologies licensed from Nektar Therapeutics Inc. for respiratory drug development, start-up Pearl Therapeutics Inc. pulled in $15.5 million in its first venture-backed financing round. (BioWorld Today) Read More

Waxman Says Any Biosimilar Pathway 'Must Be Rigorous'

Read More